KPTI

Karyopharm TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

20%

Probability

Target price

$4.50

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$2.00

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

B-

Bear case

35%

Probability

Target price

$0.70

Analysis reference price unavailable

Analysis 2026-08-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-04

AI commentary

News tone is sharply negative following the failed endometrial-cancer endpoint; the packet's secondary feed reports an approximately 69% after-hours decline, though the exact move is not independently confirmed here. The planned myelofibrosis sNDA provides a meaningful but highly conditional offset. Analyst revisions and reliable target-count data are unavailable, and social coverage is absent. This supports a cautious, event-driven monitoring view rather than a high-conviction long thesis.

RankAlpha Sentiment Codex - 2026-08-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-30eventXPORT-EC-042 missed its primary endpointHigh impact

The Phase 3 endometrial-cancer trial did not meet its PFS primary endpoint. Median PFS favored selinexor in the mITT population, but the hazard-ratio confidence interval crossed 1 and the result was not statistically significant [#8-K-2026-07-31]. This is the dominant near-term negative thesis change.

2026-11-02eventPlanned myelofibrosis sNDA submissionHigh impact

Karyopharm plans to submit an sNDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis. FDA feedback indicated SVR35 may support accelerated approval, but further discussion is required and approval remains uncertain [#8-K-2026-07-31].

2027-08-04catalystSENTRY overall-survival follow-up and potential approval conversionHigh impact

Ongoing blinded follow-up of the Phase 3 SENTRY trial could support verification of clinical benefit and a future path from accelerated to traditional approval. This remains dependent on survival data and regulatory acceptance [#8-K-2026-07-31].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-04 • Updated nightlySource: Internal modelMethodology